This site is still under development. Information, features, and some organizational
aspects of the data still need further work and will change as we continue building.

Circulating Tumor DNA

Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.

What Circulating Tumor DNA Means

Circulating tumor DNA, often called ctDNA, refers to tiny fragments of DNA that come from cancer cells and enter the bloodstream when those cells die. Unlike normal DNA fragments from healthy cells, ctDNA carries genetic changes specific to the tumor. Because these fragments float freely in the blood, doctors can detect them through a blood test sometimes called a "liquid biopsy." This test can provide important clues about the cancer without needing to remove tissue directly from the tumor.

Why ctDNA Testing Can Matter in Cancer Care

Testing for ctDNA can help doctors in several ways. It may assist in diagnosing certain types of cancer by identifying mutations linked to the disease. During treatment, measuring ctDNA levels over time can show if the cancer is responding to therapy—if ctDNA levels go down, treatment might be working. If levels rise or new mutations appear, it could suggest the cancer is growing or changing. Additionally, ctDNA testing can sometimes detect cancer recurrence earlier than traditional imaging or symptoms.

What Patients Might See or Hear About ctDNA

If ctDNA testing is part of your care, your doctor might order a blood test to better understand your tumor’s genetic makeup or to check if cancer has returned after treatment. You may see the terms "circulating tumor DNA" or "ctDNA" used interchangeably in reports, treatment plans, or clinical trial information. It’s helpful to know these terms mean the same thing to avoid confusion.

What ctDNA Testing Does Not Automatically Mean

Finding ctDNA in the blood does not always mean cancer is present or progressing. Levels can vary, and not all cancers release enough ctDNA to be detected. A negative ctDNA test does not always rule out cancer, and a positive test needs careful interpretation by your healthcare team. Because ctDNA testing is usually one part of a broader evaluation—including imaging, physical exams, and other lab tests—results are considered together to guide care.

How Doctors Use ctDNA Testing

Doctors use ctDNA testing alongside other methods to help with diagnosis, staging, treatment planning, and monitoring. Identifying specific mutations in ctDNA can help select targeted therapies designed to attack cancer cells with those changes. Tracking ctDNA over time offers a less invasive way to watch how the cancer responds to treatment or if it returns after therapy, reducing the need for repeated tissue biopsies.

Common Questions to Ask Your Care Team

If ctDNA testing is recommended or discussed, you might ask your doctor, "What does my ctDNA test tell us about my cancer?" or "How will this test affect my treatment plan?" Understanding what the test involves, why it is being done, and how the results might influence your care can help you feel more informed and involved in your treatment journey.

Understanding ctDNA in Context

Reading about ctDNA alone can be confusing. It’s best understood as part of a larger picture that includes other tests and clinical information. If ctDNA testing is part of your care, it usually means your medical team is looking for detailed information about your cancer to make the best possible decisions. This explanation is meant to provide general information and should not replace advice from your healthcare provider. Every person’s cancer and treatment plan are unique, so it’s important to discuss any questions or concerns about ctDNA testing with your medical team.

Next Steps for Patients and Caregivers

If you hear about circulating tumor DNA in your care, the next step is to talk with your doctor or nurse about what the test involves, why it is being done, and how the results might influence your care. Understanding this can help you feel more informed and involved in your treatment journey.

Sources

Public source information used for this glossary entry includes: